



# UBS Strategy Xtra Fund Balanced CHF

## Performance **Review**

UBS (Lux) Strategy Xtra SICAV - Balanced (CHF) Q-acc



### Performance (basis CHF, net of fees)<sup>1</sup>



**Past performance is not a reliable indicator of future results.**

### Performance in % (net of fees)<sup>1</sup>

in %	2020	2021	2022	2023	2024	Dec. 5 years	5 years	Ø p.a. 5 years
Fund (CHF)	2.36	8.40	-13.00	3.14	4.82	-0.80	4.36	0.86

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

**Despite ongoing conflicts in different regions of the world, the global rate-cutting cycle, the strength of the US economy and the continuing AI boom helped risky assets to a stellar performance in 2024.**

### Monthly performance

In December the fund performed negatively with 0.8%. There was no Santa Claus Rally this year, with the Fed cutting its policy rate by another 25bp but signalling fewer cuts ahead. Both global and US equities, as well as most of the fixed income space, declined over the month.

### YTD performance

YTD as of the end of December, the fund has delivered a positive performance of 4.8%. In 2024, global stocks returned 20.7% (in USD), led by the US stock market, with the S&P 500 returning above 20% for a second consecutive year. US government bonds were volatile over the year amid changing expectations regarding interest rate cuts. The biggest fixed income returns were in US and euro high-yield credit. The majority of asset classes contributed positively.

### Performance contributors

Equities led the way in terms of positive contributions over the year, thanks specifically to global equities in developed markets excluding Switzerland. On the fixed income side, corporate, high-grade, emerging market government and US high-yield bonds made the biggest contributions over the year. Hedge funds also made a notable contribution in 2024.

### Performance detractors

There were no significant detractors over the year.

### For more information

**UBS Fund Infoline: 0800 899 899**

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Sebastian Richner

Roland Kramer

Daniel Hammar

# UBS Strategy Xtra Fund Balanced CHF

## Current allocation by sub-asset class in %

	Current allocation
<b>Liquidity</b>	<b>9.5</b>
High grade bonds	13.0
USD inflation linked bonds	2.0
USD corporate bonds	5.0
EUR corporate bonds	3.0
USD high yield bonds	3.0
EUR high yield bonds	2.0
Emerging market sovereign bonds	3.0
Emerging market corporate bonds	2.0
Cash synth	-7.5
Other fixed income	0.0
<b>Bonds</b>	<b>25.5</b>
Switzerland	17.0
United States	18.4
Eurozone	5.2
United Kingdom	4.0
Emerging markets	4.2
Japan	2.0
Canada	-0.1
Australia	0.0
Sweden	-0.1
Hong Kong	-0.1
Singapore	0.1
Global	1.3
<b>Equities</b>	<b>52</b>
Hedge funds	12.0
Risk Parity	0.0
Commodity	1.0
<b>Alternative Investments</b>	<b>13</b>
<b>Total</b>	<b>100</b>

For illustrative purposes only. Current allocation may be changed at any time without prior notice. The allocation is based on the model portfolio of the strategy. Due to implementation exceptions, actual exposures may deviate. Foreign currency risks are largely hedged against the reference currency.

## 10 largest equity positions (%)

	Fund
Novartis AG	2.31
Roche Holding AG	2.22
Nestle SA	2.01
Zurich Insurance Group AG	1.30
ABB Ltd	1.18
UBS Group AG	1.08
Cie Financiere Richemont SA	1.03
Microsoft Corp	0.93
Amazon.com Inc	0.85
Swiss Re AG	0.80

## Current investment strategy

On the equity side, we maintained our overweight in US equities at the expense of cash, as well as our overweight in IT equities against global equities. We closed our long SPX put spread. Meanwhile, we kept our position in 5-year US Treasuries versus cash and 30-year US Treasuries. Currency-wise, we retained our overweight in the USD against an underweight in the CNY.

## Risks

The fund invests in equities, bonds of varying credit quality, money market securities on a global basis, as well as in alternative forms of investment such as hedge funds. It may therefore be subject to fluctuations in value. The fund may use derivatives which can reduce investment risk or give rise to additional risks (inter alia the counterparty risk). The fund can invest in less liquid assets that may be difficult to sell in the case of distressed markets. It therefore cannot be ruled out that the daily issue and redemption of fund units may be suspended temporarily. The value of a unit may fall below the purchase price. This requires an elevated risk tolerance and capacity. Every fund reveals specific risks, a description of these risks can be found in the prospectus. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

## 5 largest bond issuers (%)

	Fund
STAR Compass PLC	8.22
United States Treasury Note/Bond	2.99
United States Treasury Inflation Indexed Bonds	1.32
United States Treasury Inflation Indexed Bonds - When Issued	0.71
New York Life Global Funding	0.45

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary). © UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.